Scientific Advisory Board
Dr. Francesco Marincola - MD
Dr. Marincola is considered one of the worlds leading tumor Immunologists. He was the Chief of the Infectious Disease and Immunogenetics Section in the Department of Transfusion Medicine at the Clinical Center of the National Institute of Health in Bethesda. He was founder and serves as Editor-in-Chief, Journal of Translational Medicine and ASHI Quarterly, senior editor for the Journal of the American Society for Histocompatibility and Immunogenetics, and editor for a variety of academic journals, including Immunotherapy, Journal of Immunotherapy, Journal of Immunology, Tumori, Clinical Cancer Research, Biological Therapy, and Cancer Immunology and Immunotherapy. He is also a founding member of the Society for Immunotherapy of Cancer.
Dr. Marincola has done extensive research in tumor immunology by developing strategies for studying tumor-host interactions in the context of human genetic polymorphism and cancer heterogeneity. During his tenure as a Senior Staff Scientist with the NCI Surgery Branch, Dr. Marincola investigated the identification of the algorithm responsible for tumor rejection by immune cells particularly in the context of metastatic melanoma. In particular, the focus of his research is the optimization of strategies to study clinical material during the conduct of clinical trials. The NIH Immunogenetics laboratory is recognized nationally and internationally for the cutting edge technologies applied for the study of genetic materials at the genomic, transcriptional, epigenetic and mutational level.
Dr. Vijay Mahant, MS, PhD.
Dr. Mahant graduated from LUT in the United Kingdom and received his second post-doctorate from MD Anderson in Houston TX. Dr. Mahant is a scientist with over 30 years of experience in immune and molecular diagnostics. He has held executive positions and he is founder/co-founder of diagnostic companies with diverse experiences in Research and Development including Auto Genomics, Medi-Lite and Qualigen. He is the inventor of the “New Generation” ultra-sensitive TSH test for prostate cancer.
Dr. Mahant’s work can be seen all over the world in leading cancer institutions using his cutting edge genetic and diagnostic equipment. He has been on the forefront of the liquid biopsy and circulating tumor cell movement. His passion is to find ways to match tumors with specific drugs that might be off label and to create even better early detection diagnostic tests.
Dr. Phillip S. Kim PhD.
Dr. Kim was awarded the human genetics fellowship by the National Institute of Health (NIH) at the Cedar Sinai Medical Center. His research focused on the development of gene-therapy model via hematopoietic-stem cell mediated gene transfer and the development of ‘Geno-dynamics’ system to investigate gene function.
At Prometheus he led oncology and gastroenterology research teams to develop technologies, platforms and services for personalized/ targeted diagnostic applications with prognostic, predictive and monitoring utilities for oncology and autoimmune diseases.
His work included managing planning & execution of technical projects, clinical trials, science and technology communications, research collaborations & KOL (Key Opinion Leader) relationships, and publications.
He is the inventor of the immune pod which is positioned to address critical unmet need in oncology clinic by activating patient’s autologous immune cells specific for individual’s tumor for effective and safe cellular therapy without complex cellular manipulation. Minimally invasive approach using ‘Immuno-Pod’ maximizes tumor specific immune cell activation by exposing otherwise inaccessible tumor in vivo to contiguous ‘synthetic met’ ex vivo seamlessly integrated for each patient.
Dr. Kim’s valuable insight at CHIPSA will help guide decisions for precision medicine and specific immune response for all patients.
Dr. Francsico Silva
Francisco Silva is responsible for all laboratory operations and is involved in the development and growth of our stem cell programs at CHIPSA.
Mr. Silva previously held the position of Chief Executive Officer of two companies that made great strides in human-based biologics for both research and therapeutic applications.
From 2003 to 2007, he was Vice President of Research and Development at PrimeGen Biotech LLC. He was in charge of designing experimental methods
Mr. Silva has taught at California State Polytechnic University, where he received a master's degree in biology and an advanced tissue culture certificate. He has several patents for stem cell technologies and has had numerous papers published about stem cell research.
He joined the team here at CHIPSA in 2021 and we are looking forwards to the advancements that we can create together.